Physician profile
Mayank Agrawal
NPI 1831308063
$3,151.85
in general payments reported to CMS, 2019-2025
30 companies · $666 in 2025
The $666 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $292 · 2021: $107 · 2022: $575 · 2023: $415 · 2024: $446 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $586.67 | 2020-2025 | Watchman Access System, Rotapro, Watchman Flx |
| Abiomed | $509.55 | 2022-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $322.75 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $288.73 | 2021-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $246.21 | 2019-2020 | |
| Shockwave Medical, INC | $162.90 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.45 | 2019-2023 | Farxiga |
| Impulse Dynamics (USA) INC. | $84.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $81.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.38 | 2019-2025 | |
| Inari Medical, INC. | $66.88 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Chiesi USA, INC. | $54.86 | 2019 | |
| Abbott Laboratories | $53.81 | 2019-2025 | Navitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.09 | 2019-2020 | |
| Mylan Specialty L.P. | $43.88 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.79 | 2019-2020 | |
| Becton, Dickinson and Company | $40.04 | 2025 | True Flow |
| Amgen INC. | $38.37 | 2019-2020 | |
| Pfizer INC. | $34.60 | 2021-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $31.28 | 2024 | Arcalyst |
| Medtronic, INC. | $31.09 | 2024 | Corevalve Evolut R |
| Heartflow, INC. | $27.02 | 2025 | |
| Cordis US Corp. | $26.95 | 2025 | Mynx Control Venous |
| Penumbra, INC. | $26.00 | 2023 | Indigo System |
| Terumo Medical Corporation | $23.07 | 2019 | |
| Cvrx, INC. | $22.04 | 2025 | Barostim Neo System |
| Amarin Pharma, INC. | $19.44 | 2020 | |
| Bridgebio Pharma, INC. | $18.86 | 2025 | Attruby |
| Aegerion Pharmaceuticals, INC. | $13.92 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayank Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.